Tue.Aug 13, 2024

article thumbnail

Q&A: How PBMs Impact Patient Care

Drug Topics

Tom DePietro, PharmD, owner of DePietro’s Pharmacy in Dunmore, Pennsylvania, shared his thoughts on how patients are treated within the drug supply chain.

article thumbnail

A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients

PharmaVoice

A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.

189
189
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

COVID-19’s Impact on the Leading Causes of Death in the US

Drug Topics

Experts analyzed data from the National Center for Health Statistics on the leading causes of death in the US from the last 5 years.

503
503
article thumbnail

A potential MS ‘game changer’ could bring more safety to the table — even against viruses

PharmaVoice

Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

First FDA-Approved Digital Therapeutic to Treat Depression Now Available in App Stores

Drug Topics

Rejoyn, developed by Otsuka Pharmaceutical and Click Therapeutics, is only accessible with a prescription from a health care provider.

FDA 385
article thumbnail

STAT+: Meet the billionaire media mogul who’s taking on the food industry

STAT

WASHINGTON — The idea for Todd Wagner’s new advocacy organization FoodFight USA, he says, came to him after visiting George Clooney in Lake Como. He’s recruited Morgan Freeman, who is “obviously” a friend. He personally lobbied Arnold Schwarzenegger and current California Gov. Gavin Newsom to support food makers’ nightmare scenario — a first-in-the-nation law banning certain food additives in the state, which was signed into law last year.

FDA 145

More Trending

article thumbnail

STAT+: Why U.S. health care cybersecurity laws are better at protecting a corpse’s privacy than patients’ lives

STAT

Two days into a cyberattack on his hospital system, Nate Couture reached the end of his cyber incident plan. “We make these incident response plans and we feel great about them,” Couture, the University of Vermont Health Network chief information security officer, told other heath care cyber professionals at a recent conference. “At the end of them, they have a box that usually says something like, ‘And then IT recovers the systems.

article thumbnail

FDA Approves First Monoclonal Antibody to Treat Prurigo Nodularis

Drug Topics

Two phase 3 trials evaluating nemolizumab found that 41% of patients treated with the therapy achieved at least a 4-point reduction in itch intensity at week 16.

FDA 281
article thumbnail

STAT+: Grail announces layoffs as it looks to push forward blood-based cancer detection test

STAT

Cancer detection firm Grail announced sizable workforce cuts on Tuesday in a bid to save cash and concentrate resources on developing a blood-based test to spot early signs of dozens of cancers. The cuts will affect 30% of the biotech’s current and planned hires. Grail spokesperson Kristen Davis told STAT in an email that around 350 existing positions and 150 open roles have been eliminated.

143
143
article thumbnail

Novel Treatment Is Approved for Myelodysplastic Syndromes With Transfusion-Dependent Anemia

Drug Topics

The FDA approved imetelstat (Rytelo) in June 2024.

FDA 216
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Illumina lays out plan to boost growth by helping scientists interpret sequencing data

STAT

SAN DIEGO — The unwinding of Illumina’s ill-fated acquisition of Grail earlier this year left investors and the genomics community with a pressing question: What kind of company is Illumina going to be going forward? CEO Jacob Thaysen on Tuesday made clear that the sequencing firm, which controls about 80% of the current DNA-sequencer market, is essentially returning to its traditional role of creating instruments for researchers in academia, the biopharma industry, and health care

138
138
article thumbnail

Vivid Health brings generative AI into home healthcare, hospital-at-home services

Fierce Healthcare

Vivid Health is launching into the at-home care market to help clinical staff more efficiently fill out required, but time-consuming, assessment forms, reduce staff burnout and increase c | Digital health startup Vivid Health is a multispecialty care management platform that leverages generative AI to create patient care plans. The solution is particularly well suited for the home health sector, which struggles with capacity and burnout.

Hospitals 134
article thumbnail

Atai advances oral psychedelic in depression

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, the FDA’s recent rejection of an MDMA therapy hasn’t seemed to deter some other companies from moving ahead with psychedelics studies. We discuss that, and also some big policy developments that are coming this week.

FDA 138
article thumbnail

54% of Medicare eligibles enrolled in MA for 2024: KFF

Fierce Healthcare

Fifty-four percent of Medicare beneficiaries are enrolled in a private Medicare Advantage plan, and in seven states that figure tops 60%, according to a new report from KFF. | Fifty-four percent of Medicare beneficiaries are enrolled in a private Medicare Advantage plan, and in seven states that figure tops 60%, according to a new report from KFF.

130
130
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: Acelyrin announces layoffs, strategy shift after late-stage trial results for anti-inflammatory drug

STAT

Acelyrin, a California biotech focused on immunology and inflammatory disease, announced Tuesday that its experimental drug for a common skin disorder succeeded in a late-stage clinical trial. That’s the kind of news that’s usually accompanied by plans to apply for regulatory approval to market a new therapy. But the results didn’t show a clear edge over competing products on the market or in development.

135
135
article thumbnail

Steward Health Care agrees to sell physician group to private equity affiliate in $245M deal

Fierce Healthcare

Steward Health Care has agreed to sell its physicians network, Stewardship Health, to Rural Healthcare Group, which is owned by a private equity group. | Steward Health Care has agreed to sell its doctors network, Stewardship Health, to Rural Healthcare Group, which is owned by a private equity group.

129
129
article thumbnail

Opinion: Aspirin after a broken bone: health equity in a $5 bottle

STAT

There are few things more exciting for researchers than to mount and complete a clinical trial that could change the practice of medicine and save lives. That’s what we experienced when The New England Journal of Medicine published our findings in January 2023 that aspirin was as effective at preventing life-threatening blood clots after surgery as was a far more expensive and more painful injectable blood thinner.

Hospitals 129
article thumbnail

Industry Voices—Empowering community health workers to improve value-based care

Fierce Healthcare

In places like rural El Paso, Texas, community health workers (CHWs) help thousands of underserved individuals obtain the food, housing and medical services they need to survive. | While there’s no silver bullet to save VBC, community-based health workers are best positioned to protect it.

121
121
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: Otsuka prices depression digital therapeutic to make it widely accessible, says it’ll lose money

STAT

Otsuka Pharmaceutical has started selling Rejoyn, its Food and Drug Administration cleared prescription app that treats the symptoms of major depressive disorder. And it’s hitting the market at a low price that Otsuka hopes will entice many people to give it a try. Otsuka will make the 6-week treatment available to patients through a prescription from their existing provider or through the treatment’s website where they can connect with a clinician from Wheel Health who can prescri

Insurance 129
article thumbnail

People need to know how to use AI now

pharmaphorum

With the implementation of advancing technologies in industry comes the parallel need for suitable upskilling of the workforce – but this doesn’t as yet always pan out, and in today’s pharmaphorum podcast COO of Enthought Mike Connell discusses the growing skills gap in R&D in life sciences and the 80/20 rule with web editor Nicole Raleigh, as well as the need for correct education of people and machines, both.

119
119
article thumbnail

To approve Amgen's lung cancer med Imdelltra, FDA saw past 'large number' of missing adverse events

Fierce Pharma

When the FDA approved Amgen’s Imdelltra in May, the T-cell engager was hailed as a breakthrough for the treatment of small cell lung cancer (SCLC) and as the first DLL3-targeting therapy of potenti | In granting an accelerated approval to Amgen's first-in-class DLL3 bispecific Imdelltra, the FDA had to work through a “large number” of missing adverse events from a pivotal trial.

FDA 117
article thumbnail

STAT+: Pharmalittle: We’re reading about Novartis losing bid to block a generic, pharma deals, and more

STAT

Rise and shine, everyone, another busy day is on the way. Our mascots, for instance, got off to a particularly busy start, having spotted a feline creature nearby that sent them into a tizzy. Such is life on the campus. As for us, we are reaching for the ever-trusty coffee kettle and brewing another cup of needed stimulation. Our choice today is the oh-so smooth butter pecan.

article thumbnail

Advancing precision medicine: How real-world evidence platforms translate data into action

pharmaphorum

Learn how real-world evidence platforms use real-world data (RWD) to advance precision medicine, bridging the gap between clinical trials and real-world patient outcomes.

115
115
article thumbnail

Morning Rounds: The billionaire who wants you angry about the food supply

STAT

Want to stay on top of health news?  Sign up  to get our Morning Rounds newsletter in your inbox. We’ve got some nice awards news this morning. Yesterday, my colleague and friend Jason Mast won the the 2024 Evert Clark/Seth Payne Award , for his reporting at the intersection of medical science, business, and human lives. I asked Jason if there was a STAT story he was most proud of and he shared this heart-wrenching one from last summer when the first gene therapy was approved fo

Hospitals 110
article thumbnail

Remembering Paul Bannister, dear friend and finance manager

pharmaphorum

Our longtime Finance Director Paul Bannister was a part of the fabric of pharmaphorum almost from the beginning and an integral part of keeping the publication running. And, most importantly, he was the soul of the place and a friend to all.

111
111
article thumbnail

FDA Approves Afilbercept-Abzv as Interchangeable Biosimilar for Eylea

Pharmacy Times

The treatment is indicated to improve and maintain visual acuity in individuals with neovascular age-related macular degeneration.

FDA 107
article thumbnail

GLP-1 receptor agonists cut risk of death in inflammatory disease patients, says study

Pharmaceutical Technology

GLP-1RAs may be more effective for patients with immune diseases and type 2 diabetes than DPP-4 inhibitors, as per analysed health records.

article thumbnail

Pharma Pulse 8/13/24: How Should Biotechs Strategize for 2025, Pfizer Announces Top-Line Results of ABRYSVO for RSV & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

105
105
article thumbnail

4 foods to avoid while on Saxenda

The Checkup by Singlecare

Read any articles on the latest strategies for losing weight or ask any friends who have been trying to shed a few pounds, and you’ll likely notice a trend: The class of weight-management drugs known as glucagon-like peptide-1 (GLP-1) agonists are having a moment. Among these is the brand-name drug Saxenda (liraglutide). This prescription medication is FDA approved to regulate appetite and promote weight loss in adults with a body mass index (BMI) of 30 or higher and those with a BMI over 27 who

article thumbnail

How to Boost Your Pharmacy Profits During Flu Season

PioneerRx

The back-to-school rush is in full swing. Vacations now have to wait for cozy autumns and icy winters to happen. Once class is in session, however, the rush.

105
105
article thumbnail

Judge rebuffs Novartis bid to block generic Entresto

pharmaphorum

Novartis' attempt to stop MSN Pharma from launching a generic version of heart failure blockbuster Entresto is blocked in a US court

104
104
article thumbnail

How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Outsourcing Pharma

Driven by personal loss and inspired by the progress in disease management, Elaine has dedicated more than 20 years to the clinical trial technology industry.

104
104
article thumbnail

Study Finds Intermittent Fasting May Offset Alzheimer Disease Risk, Support Treatment Goals

Pharmacy Times

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

101
101